Stockscreener 앱 받기
4.39
6.20%
-0.29
시장 영업 전:
4.39
전일 마감가:
$4.68
열려 있는:
$4.8
하루 거래량:
34,804
Relative Volume:
0.22
시가총액:
$227.76M
수익:
$264.74M
순이익/손실:
$-49.71M
주가수익비율:
-1.0718
EPS:
-4.0959
순현금흐름:
$-43.55M
1주 성능:
+22.28%
1개월 성능:
-27.32%
6개월 성능:
+218.12%
1년 성능:
-1.79%
1일 변동 폭
$4.39
$4.80
1주일 범위
$3.585
$4.8486
52주 변동 폭
$1.305
$7.305
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
명칭
Camp 4 Therapeutics Corp
전화
617-651-8867
주소
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.39 | 242.80M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-05-27 | 개시 | Wedbush | Outperform |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | Piper Sandler | Overweight |
| 2024-11-05 | 개시 | William Blair | Outperform |
| 2022-08-16 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2021-12-22 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2021-09-24 | 재확인 | Craig Hallum | Buy |
| 2021-06-25 | 재확인 | Craig Hallum | Buy |
| 2020-12-18 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-04-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-05 | 재확인 | Craig Hallum | Buy |
| 2019-12-20 | 재확인 | Craig Hallum | Buy |
| 2019-12-20 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-01 | 재확인 | Craig Hallum | Buy |
| 2019-03-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-01-25 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-12-21 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2018-12-14 | 재확인 | B. Riley FBR | Buy |
| 2018-12-11 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | 개시 | Goldman | Neutral |
| 2018-10-15 | 개시 | Jefferies | Hold |
| 2018-09-28 | 재확인 | Craig Hallum | Hold |
| 2018-04-27 | 재확인 | Craig Hallum | Hold |
| 2018-03-08 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2018-02-16 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
모두보기
Camp 4 Therapeutics Corp 주식(CAMP)의 최신 뉴스
FMR LLC Increases Stake in Camp4 Therapeutics Corp: A Strategic Move in Biotechnology - GuruFocus
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
Downgrade Watch: Can Camp4 Therapeutics Corporation ride the EV waveTrade Analysis Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
Will Camp4 Therapeutics Corporation benefit from rising consumer demand2025 Sector Review & Verified Momentum Stock Alerts - mfd.ru
Analysis Recap: Will Camp4 Therapeutics Corporation outperform the market in YEAR2025 Stock Rankings & Weekly High Conviction Ideas - baoquankhu1.vn
Retail Trends: Is CVD Equipment Corporation stock undervalued right nowExit Point & Low Volatility Stock Recommendations - baoquankhu1.vn
Market Outlook: Will Camp4 Therapeutics Corporation stock benefit from M AJuly 2025 Final Week & Growth Focused Stock Pick Reports - baoquankhu1.vn
CAMP4 Therapeutics announces $28 million common stock offering - MSN
Signal Recap: Will Camp4 Therapeutics Corporation outperform the market in YEARMarket Growth Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
New CAMP4 hire receives option to buy 8,000 shares at $5.78 each in grant - Stock Titan
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why - sharewise.com
Published on: 2026-01-10 23:34:38 - ulpravda.ru
CAMP4 Therapeutics updates corporate investor presentation materials - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Scrip Asks... What Does 2026 Hold For Biopharma? Part 1: Capital Allocation And Dealmaking - Citeline News & Insights
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR) - The Globe and Mail
Stock Recap: What hedge fund activity signals for Camp4 Therapeutics Corporation stockMarket Performance Report & Verified Technical Signals - Улправда
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Wedbush Initiates Coverage of Camp4 Therapeutics (CAMP) with Outperform Recommendation - MSN
Insilico’s big gain after Hong Kong listing: Finance Report - biocentury.com
Sanofi adds HBV vaccine, shingles candidate via Dynavax takeout: Deals Report - BioCentury
Analysts Are Neutral on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Omeros (OMER) - The Globe and Mail
Camp4 Therapeutics signs new Watertown lease, accelerates Cambridge exit By Investing.com - Investing.com South Africa
Camp4 Therapeutics signs new Watertown lease, accelerates Cambridge exit - Investing.com
CAMP4 Therapeutics Restructures Leases and Expands Facilities - TipRanks
Deal Watch: Boehringer Signs On For Rectify’s Chronic Kidney Disease Assets - Citeline News & Insights
Is Camp4 Therapeutics Corporation a good long term investmentMarket Timing Techniques & Superior Capital Trading - earlytimes.in
Will Camp4 Therapeutics Corporation stock benefit from green energy trends2025 Technical Overview & Real-Time Buy Signal Notifications - Улправда
How Camp4 Therapeutics Corporation stock valuations compare to rivals2025 Sector Review & Real-Time Volume Triggers - Улправда
Market Rankings: How Camp4 Therapeutics Corporation stock performs in rate cut cyclesWeekly Trade Recap & Community Trade Idea Sharing - Улправда
Will Camp4 Therapeutics Corporation stock deliver better than expected guidanceTrade Entry Report & Long-Term Safe Investment Ideas - Улправда
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst - Benzinga
Quarterly Recap: Will Camp4 Therapeutics Corporation stock outperform international peersJuly 2025 Chart Watch & Detailed Earnings Play Alerts - Улправда
How Camp4 Therapeutics Corporation stock performs in rate cut cyclesJuly 2025 Update & Weekly High Momentum Picks - Улправда
CAMP4 Therapeutics (Nasdaq:CAMP) Enters Research and License Agreement with GSK - Kalkine Media
CAMP4 Therapeutics Announces $28 Million Common Stock Offering - TipRanks
CAMP4 Therapeutics (CAMP) to raise about $28M in 5M-share equity deal - Stock Titan
Will Camp4 Therapeutics Corporation stock outperform international peersGap Down & Advanced Technical Analysis Signals - Улправда
CAMP4 Therapeutics and GSK partner on ASO development for diseases By Investing.com - Investing.com Nigeria
CAMP4 Therapeutics prices $30 million common stock offering By Investing.com - Investing.com Nigeria
CAMP4 and GSK enter strategic collaboration to advance RNA-based therapeutic discoveries - PharmaLive
CAMP4, GSK form RNA therapeutics collaboration agreement - TipRanks
CAMP4 Therapeutics prices $30 million common stock offering - Investing.com India
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock - The Manila Times
CAMP4 Therapeutics and GSK partner on ASO development for diseases - Investing.com
Camp 4 Therapeutics Corp (CAMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Camp 4 Therapeutics Corp 주식 (CAMP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Polaris Management Co. VII, L. | 10% Owner |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Nashat Amir | Director |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Maricich Yuri | Chief Medical Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
6,060 |
| Gold Kelly | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
67,877 |
| Mandel-Brehm Josh | Chief Executive Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
278,417 |
| Young Richard A | Director |
Sep 11 '25 |
Buy |
1.65 |
15,151 |
24,999 |
170,010 |
1.24%
0.19%
자본화:
|
볼륨(24시간):